[
    {
        "id": "osp-10610",
        "type": "article-journal",
        "title": "The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy",
        "author": [
            {
                "family": "Al-Dughaishi",
                "given": "Malika"
            },
            {
                "family": "Shalaby",
                "given": "Asem"
            },
            {
                "family": "Boudaka",
                "given": "Khawla"
            },
            {
                "family": "Ammar",
                "given": ""
            },
            {
                "family": "Boulassel",
                "given": "Mohamed Rachid"
            },
            {
                "family": "Saleh",
                "given": "Jumana"
            }
        ],
        "URL": "https://omanscience.com/en/articles/the-value-of-programmed-death-ligand-1-expression-in-cancer-patients-treated-with-neoadjuvant-chemotherapy",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2025
                ]
            ]
        },
        "container-title": "Sultan Qaboos University Medical Journal",
        "volume": "19",
        "issue": "4",
        "page": "e277-283",
        "DOI": "10.18295/squmj.2019.19.04.002",
        "publisher": "Sultan Qaboos University",
        "ISSN": "2075-051X",
        "abstract": "Programmed death ligand 1 (PD-L1) is an inhibitory molecule expressed by cancer cells to supress T-cell activity and escape anti-tumour immunity. The role of PD-L1 in cancer has been studied extensively as it is considered an important immune checkpoint against immune over-activation through its interaction with Programmed death receptor 1 (PD-1) expressed on activated lymphocytes. PD-L1 expression was found to be enhanced by chemotherapy through different proliferation pathways. However, the predictive and prognostic value for PD-L1 expression in cancer patients treated with neoadjuvant chemotherapy (NAC) is not yet established. This review focused on the potential effects of chemotherapy on PD-L1 expression and the role of PD-L1 as a prognostic and predictive marker in NAC-treated cancer patients. In addition, the potential use of this marker in clinical practice is discussed."
    }
]